{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124598","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.352780+00:00","generated_at":"2026-05-30T02:02:50.082558+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mereo BioPharma Q3 net loss $15M; cash $80.5M; amends AstraZeneca deal with $114.3M milestone potential","bullets":["Amended AstraZeneca license agreement modifies development milestones; potential future payments up to $114.3M in cash and ADSs; issued 2.04M shares and paid $0.5M.","Q3 net loss $15.0M vs $6.5M YoY, driven by $6.4M foreign exchange loss; R&D down 12% to $3.2M.","Cash $80.5M as of Sep 30, 2024 (up from $57.4M Dec 2023); expected to fund operations into 2027.","Setrusumab received FDA Breakthrough Therapy designation for osteogenesis imperfecta; Phase 3 topline data expected 2025.","Alvelestat remains on track to be Phase 3-ready by end of 2024; partnership discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124598","json":"https://secwatch.observer/filing/0000950170-24-124598.json","markdown":"https://secwatch.observer/filing/0000950170-24-124598.md","text":"https://secwatch.observer/filing/0000950170-24-124598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/0000950170-24-124598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000095017024124598/mreo-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:02:50.082558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}